Logo image of MBRX

MOLECULIN BIOTECH INC (MBRX) Stock Fundamental Analysis

NASDAQ:MBRX - US60855D3098 - Common Stock

0.3924 USD
0 (-0.18%)
Last: 8/29/2025, 8:00:01 PM
0.398 USD
+0.01 (+1.43%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MBRX. MBRX was compared to 542 industry peers in the Biotechnology industry. MBRX may be in some trouble as it scores bad on both profitability and health. MBRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MBRX has reported negative net income.
In the past year MBRX has reported a negative cash flow from operations.
MBRX had negative earnings in each of the past 5 years.
In the past 5 years MBRX always reported negative operating cash flow.
MBRX Yearly Net Income VS EBIT VS OCF VS FCFMBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -122.96%, MBRX is not doing good in the industry: 80.26% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -122.96%
ROE N/A
ROIC N/A
ROA(3y)-85.68%
ROA(5y)-67.14%
ROE(3y)-177.93%
ROE(5y)-130.32%
ROIC(3y)N/A
ROIC(5y)N/A
MBRX Yearly ROA, ROE, ROICMBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

MBRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBRX Yearly Profit, Operating, Gross MarginsMBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for MBRX has been increased compared to 1 year ago.
Compared to 5 years ago, MBRX has more shares outstanding
There is no outstanding debt for MBRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MBRX Yearly Shares OutstandingMBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
MBRX Yearly Total Debt VS Total AssetsMBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -14.43, we must say that MBRX is in the distress zone and has some risk of bankruptcy.
MBRX's Altman-Z score of -14.43 is on the low side compared to the rest of the industry. MBRX is outperformed by 79.70% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.43
ROIC/WACCN/A
WACCN/A
MBRX Yearly LT Debt VS Equity VS FCFMBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

MBRX has a Current Ratio of 1.15. This is a normal value and indicates that MBRX is financially healthy and should not expect problems in meeting its short term obligations.
MBRX has a Current ratio of 1.15. This is amonst the worse of the industry: MBRX underperforms 85.79% of its industry peers.
A Quick Ratio of 1.15 indicates that MBRX should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.15, MBRX is not doing good in the industry: 85.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 1.15
MBRX Yearly Current Assets VS Current LiabilitesMBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.01% over the past year.
EPS 1Y (TTM)62.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.87% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.82%
EPS Next 2Y35.1%
EPS Next 3Y21.6%
EPS Next 5Y20.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBRX Yearly Revenue VS EstimatesMBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2029 2030 2031 2032 50M 100M 150M 200M
MBRX Yearly EPS VS EstimatesMBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MBRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBRX Price Earnings VS Forward Price EarningsMBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBRX Per share dataMBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4

4.3 Compensation for Growth

MBRX's earnings are expected to grow with 21.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.1%
EPS Next 3Y21.6%

More info and screens

0

5. Dividend

5.1 Amount

MBRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULIN BIOTECH INC

NASDAQ:MBRX (8/29/2025, 8:00:01 PM)

After market: 0.398 +0.01 (+1.43%)

0.3924

0 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-06 2025-11-06
Inst Owners4.89%
Inst Owner Change-70.73%
Ins Owners3.45%
Ins Owner Change25.14%
Market Cap11.89M
Analysts82.22
Price Target7.14 (1719.57%)
Short Float %13.9%
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.05%
Min EPS beat(2)-32.22%
Max EPS beat(2)-21.89%
EPS beat(4)1
Avg EPS beat(4)0.72%
Min EPS beat(4)-32.22%
Max EPS beat(4)71.5%
EPS beat(8)4
Avg EPS beat(8)5.04%
EPS beat(12)6
Avg EPS beat(12)6.29%
EPS beat(16)9
Avg EPS beat(16)9.7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-34.38%
EPS NQ rev (1m)10.84%
EPS NQ rev (3m)78.74%
EPS NY rev (1m)13.99%
EPS NY rev (3m)18.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.4
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS-0.24
TBVpS-0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.68%
ROA(5y)-67.14%
ROE(3y)-177.93%
ROE(5y)-130.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 1.15
Altman-Z -14.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)53.16%
Cap/Depr(5y)71.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
EPS Next Y79.82%
EPS Next 2Y35.1%
EPS Next 3Y21.6%
EPS Next 5Y20.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.55%
EBIT Next 3Y-6.25%
EBIT Next 5Y27.59%
FCF growth 1Y17.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.84%
OCF growth 3YN/A
OCF growth 5YN/A